{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"31.2","value":"58.8"},{"groupId":"OG002","spread":"18.6","value":"65.0"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"65.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Screening"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"21.4","value":"3.8"},{"groupId":"OG002","spread":"15.0","value":"-8.3"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Lymphodepleting Chemotherapy Day -5"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"8.5","value":"1.3"},{"groupId":"OG002","spread":"8.3","value":"-0.5"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Day 0"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.0","value":"-10.0"},{"groupId":"OG002","spread":"15.3","value":"-0.6"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"17.7","value":"2.5"},{"groupId":"OG002","spread":"26.1","value":"6.4"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"21.2","value":"-5.0"},{"groupId":"OG002","spread":"13.1","value":"-3.8"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG001","spread":"NA","value":"-20.1"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG002","spread":"NA","value":"50.0"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Month 9"},{"categories":[{"measurements":[{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG001","spread":"NA","value":"-10.0"},{"groupId":"OG002","spread":"40.9","value":"20.0"},{"comment":"Standard Deviation cannot be estimated for one participant.","groupId":"OG003","spread":"NA","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"The EQ-VAS recorded the participant's self-rated health on a vertical VAS, where the end points were labeled \"the best health you can imagine\" and \"the worst health you can imagine.\" The EQ-VAS could be used as a quantitative measure of a health outcome that reflected the participant's own judgment. The EQ-VAS recorded the participant's self-rated health on a vertical VAS, with a score numbered from 0 to 100, where '100 meant the best health you can imagine' and '0 meant the worst health you can imagine\".","dispersionType":"Standard Deviation","groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"OG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"paramType":"MEAN","populationDescription":"Participants in substudies B, C and D, in the Safety Analysis Set with available data were analyzed. Substudy A was withdrawn, therefore no participants were enrolled in it. Hence, data is not available.","reportingStatus":"POSTED","timeFrame":"Screening, Day -5, Day 0, Day 28, Month 3, Month 6, Month 9 and Month 12","title":"All Substudies (Substudies A, B, C and D): Change From Screening in the EQ-ED-5L Visual Analogue Scale (EQ-VAS) Score","type":"SECONDARY","unitOfMeasure":"score on scale"}